| Bioactivity | KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRASG12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer[1]. |
| Formula | C28H35ClN8O2 |
| Molar Mass | 551.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fu S, et al. Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer. |